

Evaluating the Impact of Tertinat on Patients with Atherosclerosis-Related Cardiovascular Diseases

NCT06590012

Status	RECRUITING
Phase	Phase 2
Sponsor	Institute for Atherosclerosis Research, Russia
Enrollment	556 participants

Key Eligibility Criteria

Inclusion (4)

- Patients with cardiovascular disease of atherosclerotic origin, requiring hospitalization and treatment hospital conditions. Cardiovascular diseases may include the following nosology: Coronary heart disease; Atherosclerosis. Diseases include (and/or) atherosclerotic lesions of the coronary arteries, brachiocephalic arteries, limb arteries, renal arteries requiring surgical revascularization.
- Patients who have undergone a complex of necessary by current standards for their disease instrumental and laboratory examinations, including ECG, severity assessment vascular stenosis (ultrasound, CT, angiography), including large arteries, brachiocephalic arteries, femoral arteries, biochemical blood test assessing the level of general cholesterol, triglycerides, lipoproteins low density, high lipoprotein density, glucose level.
- Possibility of monitoring the patient - Possibility every 12 months call the patient for questioning and examination.
- The patient has signed informed consent.

Exclusion (9)

- Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association).
- Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance < 30 ml / min according to the Cockcroft-Gault Equation)
- Systemic autoimmune diseases in medical history, including: rheumatoid arthritis, systemic lupus erythematosus, autoimmune thyroiditis, autoimmune vasculitis, ulcerative colitis.
- Significant weight loss ($> 10\%$ of body weight in the previous year) of unknown etiology.
- Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.).

... and 4 more (see full listing online)

Locations (1 total)

Institute for Atherosclerosis Research, Moscow, Russia